Interpretation of Updates for Diagnosis and Staging Criterion of NIA-AA Alzheimer's Disease(2024 Edition):Diagnostic and Therapeutic Significance of Multimodal Imaging
10.3969/j.issn.1005-5185.2025.05.002
- VernacularTitle:2024版NIA-AA阿尔茨海默病诊断与分期标准更新解读:多模态影像的诊疗意义
- Author:
Xiaofei HU
1
;
Li GUI
;
Xiao CHEN
;
Dingde HUANG
Author Information
1. 陆军军医大学第一附属医院核医学科,重庆 400038
- Publication Type:Journal Article
- Keywords:
Alzheimer's disease;
Positron-emission tomography;
Molecular imaging;
Biomarkers;
Amyloid β-protein;
tau proteins;
Diagnosis;
Interpretation
- From:
Chinese Journal of Medical Imaging
2025;33(5):454-460
- CountryChina
- Language:Chinese
-
Abstract:
The National Institute on Aging-Alzheimer's Association(NIA-AA)released the"Revised criteria for diagnosis and staging of Alzheimer's disease"in 2024,representing a significant update following the 2011 and 2018 frameworks.This new standard aims to advance Alzheimer's disease diagnosis and treatment from a"clinical-pathological"model to a"precision biology"era,improving early diagnosis rates and guiding precise therapeutic interventions.Nuclear medicine molecular imaging plays an irreplaceable role in Alzheimer's disease diagnosis and staging,with key updates in the 2024 standard being the replacement of traditional clinical diagnosis with biological definitions and the hierarchical classification of biomarkers.This article focuses on interpreting the core positioning and clinical application value of multimodal imaging technologies within the new standard framework,particularly the critical roles of amyloid β-protein PET and tau PET in early diagnosis,biological staging and treatment monitoring of Alzheimer's disease,aiming to provide guidance for clinical practice.
